StreetInsider.com News Articles

Aclarion study finds Nociscan agrees with discography in 87% of cases

Thu, 22 Oct 2026 07:01:01 -0400

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the publication of a peer-reviewed study in the European Spine Journal finding that its Nociscan tool agreed with low-pressure provocative discography in identifying painful lumbar discs in up to 87% of cases.

The study, conducted at the London Spine Clinic, evaluated Nociscan against discography — an invasive procedure considered a reference standard for identifying painful spinal discs — across 55 lumbar discs in 20 consecutive patients being evaluated for surgical treatment.

Discography involves inserting a needle into a spinal disc and injecting fluid to reproduce a patient's pain. The procedure can cause pain flare-ups lasting several

Aclarion study finds Nociscan agrees with discography in 87% of cases

Thu, 22 Oct 2026 07:01:01 -0400

Discography involves inserting a needle into a spinal disc and injecting fluid to reproduce a patient's pain. The procedure can cause pain flare-ups lasting several

Aclarion study finds Nociscan agrees with discography in 87% of cases

Thu, 22 Oct 2026 07:01:01 -0400

Discography involves inserting a needle into a spinal disc and injecting fluid to reproduce a patient's pain. The procedure can cause pain flare-ups lasting several

Aclarion study finds Nociscan agrees with discography in 87% of cases

Thu, 22 Oct 2026 07:01:01 -0400

Discography involves inserting a needle into a spinal disc and injecting fluid to reproduce a patient's pain. The procedure can cause pain flare-ups lasting several

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Thu, 22 Oct 2026 07:00:00 -0400

Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of cases
Nociscan also spared patients the needles, added cost, and recovery time that is often associated with discography
Authors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patients
Bolsters the case for physician adoption and payor support for Nociscan

BROOMFIELD, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Thu, 22 Oct 2026 07:00:00 -0400

Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of cases
Nociscan also spared patients the needles, added cost, and recovery time that is often associated with discography
Authors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patients
Bolsters the case for physician adoption and payor support for Nociscan

BROOMFIELD, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Thu, 22 Oct 2026 07:00:00 -0400

Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of cases
Nociscan also spared patients the needles, added cost, and recovery time that is often associated with discography
Authors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patients
Bolsters the case for physician adoption and payor support for Nociscan

BROOMFIELD, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Thu, 22 Oct 2026 07:00:00 -0400

Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of cases
Nociscan also spared patients the needles, added cost, and recovery time that is often associated with discography
Authors conclude Nociscan “may, in time, replace provocative lumbar discography” in appropriately selected patients
Bolsters the case for physician adoption and payor support for Nociscan

BROOMFIELD, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),

Aclarion reports 85% scan volume growth in Q3 2026

Tue, 20 Oct 2026 07:00:42 -0400

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company focused on chronic low back pain, reported 85% year-over-year scan volume growth in the third quarter of 2026, according to a shareholder letter published by Chief Executive Officer Brent Ness.

Scan volumes grew 117% for the nine months ended September 30, 2026. The company's Nociscan platform uses magnetic resonance spectroscopy and proprietary algorithms to help physicians identify sources of chronic low back pain.

The European Spine Journal published peer-reviewed data supporting MRS as a potential alternative to provocative discography, adding to the company's clinical evidence base. Aclarion said the publication is intended to

Aclarion reports 85% scan volume growth in Q3 2026

Tue, 20 Oct 2026 07:00:42 -0400

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company focused on chronic low back pain, reported 85% year-over-year scan volume growth in the third quarter of 2026, according to a shareholder letter published by Chief Executive Officer Brent Ness.

Scan volumes grew 117% for the nine months ended September 30, 2026. The company's Nociscan platform uses magnetic resonance spectroscopy and proprietary algorithms to help physicians identify sources of chronic low back pain.

The European Spine Journal published peer-reviewed data supporting MRS as a potential alternative to provocative discography, adding to the company's clinical evidence base. Aclarion said the publication is intended to

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Tue, 20 Oct 2026 07:00:00 -0400

85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026
European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discography
CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment
Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end
$14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Tue, 20 Oct 2026 07:00:00 -0400

85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026
European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discography
CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment
Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end
$14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Tue, 20 Oct 2026 07:00:00 -0400

85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026
European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discography
CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment
Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end
$14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Tue, 20 Oct 2026 07:00:00 -0400

85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026
European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discography
CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment
Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end
$14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund

Aclarion to Present at the 20th Annual LD Micro Main Event

Tue, 13 Oct 2026 07:00:00 -0400

BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Aclarion is scheduled to present on Tuesday, October 20, 2026 at 11:30 AM PT. Brent Ness, Chief Executive Officer will represent the company.

Presentation Details

Event: LD Micro Main Event XX
Date: Tuesday, October 20, 2026
Time: 11:30 AM
Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
Webcast: https://ldmicroevents.com/

To register for the event, please contact:

Aclarion to Present at the 20th Annual LD Micro Main Event

Tue, 13 Oct 2026 07:00:00 -0400

BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Aclarion is scheduled to present on Tuesday, October 20, 2026 at 11:30 AM PT. Brent Ness, Chief Executive Officer will represent the company.

Presentation Details

Event: LD Micro Main Event XX
Date: Tuesday, October 20, 2026
Time: 11:30 AM
Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
Webcast: https://ldmicroevents.com/

To register for the event, please contact:

Aclarion to Present at the 20th Annual LD Micro Main Event

Tue, 13 Oct 2026 07:00:00 -0400

BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Aclarion is scheduled to present on Tuesday, October 20, 2026 at 11:30 AM PT. Brent Ness, Chief Executive Officer will represent the company.

Presentation Details

Event: LD Micro Main Event XX
Date: Tuesday, October 20, 2026
Time: 11:30 AM
Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
Webcast: https://ldmicroevents.com/

To register for the event, please contact:

Aclarion to Present at the 20th Annual LD Micro Main Event

Tue, 13 Oct 2026 07:00:00 -0400

BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Aclarion is scheduled to present on Tuesday, October 20, 2026 at 11:30 AM PT. Brent Ness, Chief Executive Officer will represent the company.

Presentation Details

Event: LD Micro Main Event XX
Date: Tuesday, October 20, 2026
Time: 11:30 AM
Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
Webcast: https://ldmicroevents.com/

To register for the event, please contact:

Aclarion revises CLARITY trial criteria after missing Q4 enrollment goal

Thu, 08 Oct 2026 07:01:33 -0400

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced it has broadened the enrollment criteria for its pivotal CLARITY clinical trial after enrollment failed to reach the pace needed to support a fourth-quarter 2026 initial readout.

The Broomfield, Colo.-based healthcare technology company said the revised inclusion and exclusion criteria have received Institutional Review Board (IRB) approval at 9 of 11 active trial sites. The remaining two active sites are using the revised criteria for screening purposes ahead of local IRB approval. The new criteria will also apply to all newly added sites, including NYU.

According to the company, the original criteria were designed to eliminate

Aclarion revises CLARITY trial criteria after missing Q4 enrollment goal

Thu, 08 Oct 2026 07:01:33 -0400

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced it has broadened the enrollment criteria for its pivotal CLARITY clinical trial after enrollment failed to reach the pace needed to support a fourth-quarter 2026 initial readout.

The Broomfield, Colo.-based healthcare technology company said the revised inclusion and exclusion criteria have received Institutional Review Board (IRB) approval at 9 of 11 active trial sites. The remaining two active sites are using the revised criteria for screening purposes ahead of local IRB approval. The new criteria will also apply to all newly added sites, including NYU.

According to the company, the original criteria were designed to eliminate

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Thu, 08 Oct 2026 07:00:00 -0400

New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace
Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases
Overall trial duration remains on track

BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Thu, 08 Oct 2026 07:00:00 -0400

New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace
Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases
Overall trial duration remains on track

BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Thu, 08 Oct 2026 07:00:00 -0400

New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace
Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases
Overall trial duration remains on track

BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Thu, 08 Oct 2026 07:00:00 -0400

New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace
Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases
Overall trial duration remains on track

BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Tue, 29 Sep 2026 07:00:00 -0400

NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research
CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain
Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)

BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare